Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.46 |
| ▸ | CD44 | P16070 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | OXTR | P30559 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | PRCP | P42785 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11691031 | 0.98 | PNMT (0.45) | PNMTCD44MAOBHTR2CTSHR | |
| SCHEMBL4500368 | 0.76 | MAOB (0.39) | PNMTCD44MAOBHTR2CALOX15 | |
| SCHEMBL2062312 | 0.69 | TSHR (0.53) | PNMTCD44MAOBHTR2CTSHR | |
| SCHEMBL4489100 | 0.68 | NPC1 (0.42) | MAOBHTR2CTSHRCA12CA1 | |
| SCHEMBL13889191 | 0.67 | CA12 (0.42) | PNMTCD44MAOBHTR2CTSHR | |
| SCHEMBL34906 | 0.64 | — | — | |
| SCHEMBL33555 | 0.64 | — | — | |
| SCHEMBL29351986 | 0.64 | — | — | |
| SCHEMBL4465325 | 0.64 | TSHR (0.71) | PNMTCD44MAOBHTR2CTSHR | |
| SCHEMBL6740589 | 0.64 | TSHR (0.41) | PNMTCD44MAOBTSHRCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4041048-A | ANTIINFLAMMATORY AGENTS, CNS DEPRESSANTS | GRUPPO LEPETIT S.P.A. (IT) | 1977-08-09 | — | — | US | claimed |
| US-20250011338-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2025-01-09 | — | — | US | disclosed |
| US-12129263-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2024-10-29 | — | — | US | disclosed |
| CN-110913858-B | Kinase inhibitors and uses thereof | 戴纳立制药公司 | 2024-09-24 | — | — | CN | disclosed |
| US-20220041620-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2022-02-10 | — | — | US | disclosed |
| US-11203600-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2021-12-21 | — | — | US | disclosed |
| EP-3624797-A1 | KINASE INHIBITORS AND USES THEREOF | Denali Therapeutics Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2020-03-19 | — | — | US | disclosed |
| WO-2018213632-A1 | KINASE INHIBITORS AND USES THEREOF | DENALI THERAPEUTICS INC. (US) | 2018-11-22 | — | — | WO | disclosed |
| US-8252814-B2 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-28 | — | — | US | disclosed |
| EP-1310490-A1 | GPR14 ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
| EP-1308513-A1 | USE OF POLYPEPTIDE | Takeda Chemical Industries, Ltd. (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-6534496-B1 | Prophylactic and/or therapeutic drug for obesity and obesity associated diseasestor diabetes with a reduced risk for central side effects and high universality in usage. Another object of the a lipolytic agent, or a prophylactic and/or | TAKEDA CHEMICAL INDUSTRIES, INC. (JP) | 2003-03-18 | — | — | US | disclosed |
| US-6319916-B1 | CHOLINESTERASE INHIBITOR FOR SENILE DEMENTIA AND ALZHEIMER'S TREATMENT | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-11-20 | — | — | US | disclosed |
| EP-1118322-A1 | DRUGS FOR IMPROVING VESICAL EXCRETORY STRENGTH | Takeda Chemical Industries, Ltd. (JP) | 2001-07-25 | — | — | EP | disclosed |
| EP-0975624-A1 | THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS | Takeda Chemical Industries, Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998046590-A1 | THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-22 | — | — | WO | disclosed |
| EP-0567090-A2 | Benzoxazepine derivatives as cholinesterase inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-10-27 | — | — | EP | disclosed |
| US-4041048-A | ANTIINFLAMMATORY AGENTS, CNS DEPRESSANTS | GRUPPO LEPETIT S.P.A. (IT) | 1977-08-09 | — | — | US | disclosed |
| US-4041048-A | ANTIINFLAMMATORY AGENTS, CNS DEPRESSANTS | GRUPPO LEPETIT S.P.A. (IT) | 1977-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011338-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | PNMT 3082/4885CD44 3586/4885MAOB 2416/4885 |
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | PNMT 3082/4885CD44 3586/4885MAOB 2416/4885 |
| US-11203600-B2 | Kinase inhibitors and uses thereof | MAP3K20, MAP3K6, MAP3K19 | PNMT 3082/4885CD44 3586/4885MAOB 2416/4885 |
| US-20220041620-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | PNMT 3082/4885CD44 3586/4885MAOB 2416/4885 |
| US-12129263-B2 | Kinase inhibitors and uses thereof | MAP3K20, MAP3K6, MAP3K19 | PNMT 3082/4885CD44 3586/4885MAOB 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.